Canabidiol no tratamento da epilepsia farmacorresistente: uma revisão baseada em evidências científicas
Revista ft · 31.05.2026 · 30 (158) · 01-13
DOI: 10.69849/yezzjm31 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 31.05.2026. Verfasst von Drielle Christine do Monte Mascarenhas und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Epilepsy is a chronic neurological disorder characterized by abnormal electrical discharges in the brain, responsible for recurrent seizures that compromise the physical, cognitive, emotional, and social aspects of affected individuals. Among clinical cases, refractory epilepsy stands out as a condition in which patients do not achieve satisfactory seizure control even after the appropriate use of conventional antiepileptic drugs. In this context, cannabidiol (CBD), a non-psychoactive compound derived from Cannabis sativa, has been widely investigated due to its anticonvulsant potential and its therapeutic application in drug-resistant epilepsies.
Objectives
The present study aimed to understand the mechanisms of action of cannabidiol and its therapeutic effects in the treatment of epilepsy. Specifically, the study sought to compare the effects of conventional treatment with the use of CBD, understand its mechanisms of action in the epileptic context, and evaluate the adverse effects, toxicity, and safety profile associated with its use, especially in refractory cases. Justification. The relevance of this research is based on the need to expand scientific knowledge regarding therapeutic alternatives capable of improving the quality of life of patients with refractory epilepsy, contributing to academic, clinical, and social advances related to the medicinal use of Cannabis sativa. Methodology. This study consists of systematic literature review with a qualitative and descriptive approach, developed through the analysis of scientific articles published between 2015 and 2025 in the PubMed, Scielo, and Google Scholar databases. Results and Discussion. The results demonstrated that cannabidiol has therapeutic potential as an adjuvant treatment in severe and refractory epilepsies, promoting a reduction in the frequency and intensity of seizures. It was also observed that CBD acts by modulating neuronal excitability through the endocannabinoid system. Despite the benefits, adverse effects such as drowsiness, fatigue, gastrointestinal alterations, and elevated liver enzymes were reported, highlighting the need for continuous medical follow-up.
Conclusion
It is concluded that cannabidiol represents a promising therapeutic alternative in the complementary management of drug-resistant epilepsy, although its use should occur in a careful, regulated, and evidence-based manner. Further studies are still necessary to consolidate its long-term efficacy and safety.
Zitieren
APA
Mascarenhas, D. C. D. M., Tavares, I. L. L., Rocha, F. E. D. S., & Tourinho, L. D. S. O. (2026). Canabidiol no tratamento da epilepsia farmacorresistente: uma revisão baseada em evidências científicas. Revista ft, 30(158), 01-13. https://doi.org/10.69849/yezzjm31
Vancouver
Mascarenhas DCDM, Tavares ILL, Rocha FEDS, Tourinho LDSO. Canabidiol no tratamento da epilepsia farmacorresistente: uma revisão baseada em evidências científicas. Revista ft. 2026;30(158):01-13. doi:10.69849/yezzjm31
BibTeX
@article{Mascarenhas2026,
author = {Mascarenhas, Drielle Christine do Monte and Tavares, Isabela Lavigne Lemos and Rocha, Flávia Emanuelly da Silva and Tourinho, Luciano de Souza Oliveira},
title = {Canabidiol no tratamento da epilepsia farmacorresistente: uma revisão baseada em evidências científicas},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {158},
pages = {01--13},
doi = {10.69849/yezzjm31}
}
EUVIMED